Literature DB >> 20959120

Nicorandil normalizes prolonged repolarisation in the first transgenic rabbit model with Long-QT syndrome 1 both in vitro and in vivo.

Jürgen Biermann1, Kezhong Wu, Katja E Odening, Stefan Asbach, Gideon Koren, Xuwen Peng, Manfred Zehender, Christoph Bode, Michael Brunner.   

Abstract

Transgenic rabbits expressing loss-of-function pore mutants of the human gene KCNQ1 (K(v)LQT1-Y315S) have a Long QT-Syndrome 1 (LQT1) phenotype. We evaluated for the first time the effect of nicorandil, an opener of ATP-sensitive potassium channels, and of isoproterenol on cardiac action potential duration and heart rate dependent dispersion of repolarisation in transgenic LQT1 rabbits. In vivo LQT1 and littermate control were subjected to transvenous electrophysiological studies; in vitro monophasic action potentials were recorded from explanted Langendorff-perfused hearts. In vivo ventricular effective refractory periods (VERP) at the right ventricular base were significantly prolonged in LQT1 as compared to littermate control, resulting in a more pronounced VERP dispersion in LQT1. This difference in VERP dispersion between LQT1 and littermate control disappeared after infusion of nicorandil. In vitro, mean action potential durations (APD(75) and APD(90)) of LQT1 were significantly prolonged compared to littermate control at baseline. Nicorandil decreased APD(75) and APD(90) in LQT1 and littermate control at all stimulated heart rates. After adding nicorandil, the APD(90) at all hearts rates and the APD(75) at high heart rates were no longer different. Dispersion of repolarisation (∆APD(75) and ∆APD(90)) was heart rate dependently decreased after nicorandil at all tested stimulation cycle lengths only in LQT1. We demonstrated phenotypic differences of LQT1 and littermate control in vivo and in vitro. Nicorandil 20μmol/l improved repolarisation abnormalities and heterogeneities in transgenic LQT1 rabbits.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959120      PMCID: PMC2997896          DOI: 10.1016/j.ejphar.2010.10.016

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  48 in total

1.  The long Q-T syndrome.

Authors:  P J Schwartz; M Periti; A Malliani
Journal:  Am Heart J       Date:  1975-03       Impact factor: 4.749

Review 2.  Similarity and dissimilarity in the mode and mechanism of action between nicorandil and classical nitrates: an overview.

Authors:  N Taira
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

3.  Electrical alternans and cardiac electrical instability.

Authors:  J M Smith; E A Clancy; C R Valeri; J N Ruskin; R J Cohen
Journal:  Circulation       Date:  1988-01       Impact factor: 29.690

4.  Maps of optical action potentials and NADH fluorescence in intact working hearts.

Authors:  G Salama; R Lombardi; J Elson
Journal:  Am J Physiol       Date:  1987-02

5.  Systematic assessment of patients with unexplained cardiac arrest: Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER).

Authors:  Andrew D Krahn; Jeffrey S Healey; Vijay Chauhan; David H Birnie; Christopher S Simpson; Jean Champagne; Martin Gardner; Shubhayan Sanatani; Derek V Exner; George J Klein; Raymond Yee; Allan C Skanes; Lorne J Gula; Michael H Gollob
Journal:  Circulation       Date:  2009-07-13       Impact factor: 29.690

6.  Transmural action potential repolarization heterogeneity develops postnatally in the rabbit.

Authors:  Salim F Idriss; Patrick D Wolf
Journal:  J Cardiovasc Electrophysiol       Date:  2004-07

7.  Prolonged action potential durations, increased dispersion of repolarization, and polymorphic ventricular tachycardia in a mouse model of proarrhythmia.

Authors:  Larissa Fabritz; Paulus Kirchhof; Michael R Franz; Lars Eckardt; Gerold Mönnig; Peter Milberg; Günter Breithardt; Wilhelm Haverkamp
Journal:  Basic Res Cardiol       Date:  2003-02       Impact factor: 17.165

8.  Intravenous nicorandil can reduce QT dispersion and prevent bradyarrhythmia during percutaneous transluminal coronary angioplasty of the right coronary artery.

Authors:  Hiroyasu Ueda; Tomoshige Hayashi; Kei Tsumura; Kiyomichi Yoshimaru; Yasunori Nakayama; Junichi Yoshikawa
Journal:  J Cardiovasc Pharmacol Ther       Date:  2004-09       Impact factor: 2.457

9.  Clinical significance of ventricular fibrillation-flutter induced by ventricular programmed stimulation.

Authors:  L A DiCarlo; F Morady; A B Schwartz; E N Shen; J M Baerman; R B Krol; M M Scheinman; R J Sung
Journal:  Am Heart J       Date:  1985-05       Impact factor: 4.749

10.  Intravenous nicorandil can reduce the occurrence of ventricular fibrillation and QT dispersion in patients with successful coronary angioplasty in acute myocardial infarction.

Authors:  Hiroyasu Ueda; Yasunori Nakayama; Kei Tsumura; Kiyomichi Yoshimaru; Tomoshige Hayashi; Junichi Yoshikawa
Journal:  Can J Cardiol       Date:  2004-05-01       Impact factor: 5.223

View more
  7 in total

Review 1.  Modulation of the QT interval duration in hypertension with antihypertensive treatment.

Authors:  Jan Klimas; Peter Kruzliak; Simon W Rabkin
Journal:  Hypertens Res       Date:  2015-03-19       Impact factor: 3.872

Review 2.  On the emerging role of rabbit as human disease model and the instrumental role of novel transgenic tools.

Authors:  V Duranthon; N Beaujean; M Brunner; K E Odening; A Navarrete Santos; I Kacskovics; L Hiripi; E J Weinstein; Z Bosze
Journal:  Transgenic Res       Date:  2012-03-02       Impact factor: 2.788

3.  Modulation of hERG potassium channel gating normalizes action potential duration prolonged by dysfunctional KCNQ1 potassium channel.

Authors:  Hongkang Zhang; Beiyan Zou; Haibo Yu; Alessandra Moretti; Xiaoying Wang; Wei Yan; Joseph J Babcock; Milena Bellin; Owen B McManus; Gordon Tomaselli; Fajun Nan; Karl-Ludwig Laugwitz; Min Li
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-28       Impact factor: 11.205

Review 4.  Transgenic rabbit models for studying human cardiovascular diseases.

Authors:  Xuwen Peng
Journal:  Comp Med       Date:  2012-12       Impact factor: 0.982

Review 5.  Congenital long QT syndromes: prevalence, pathophysiology and management.

Authors:  Alon Barsheshet; Olena Dotsenko; Ilan Goldenberg
Journal:  Paediatr Drugs       Date:  2014-12       Impact factor: 3.022

6.  Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation.

Authors:  Elena Matsa; Divya Rajamohan; Emily Dick; Lorraine Young; Ian Mellor; Andrew Staniforth; Chris Denning
Journal:  Eur Heart J       Date:  2011-03-02       Impact factor: 29.983

7.  Pronounced effects of HERG-blockers E-4031 and erythromycin on APD, spatial APD dispersion and triangulation in transgenic long-QT type 1 rabbits.

Authors:  David Ziupa; Julia Beck; Gerlind Franke; Stefanie Perez Feliz; Maximilian Hartmann; Gideon Koren; Manfred Zehender; Christoph Bode; Michael Brunner; Katja E Odening
Journal:  PLoS One       Date:  2014-09-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.